



AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA309)

NICE GUIDANCE ISSUED APRIL 2014

(Refer to NICE website for full guidance on NICE recommendations,
including any specific restrictions on the use of the technology)

Pemetrexed (Alimta[®])

Monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following induction therapy with pemetrexed in combination with cisplatin

Eli Lilly & Co Ltd

February 2012

Statement of Advice

ADVICE: in the absence of a submission from the holder of the marketing authorisation, pemetrexed (Alimta[®]) cannot be endorsed for use within NHS Wales as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following induction therapy with pemetrexed in combination with cisplatin.

Additional note:

For the use of pemetrexed as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following induction treatment with gemcitabine, paclitaxel or docetaxel, please refer to NICE technology appraisal guidance 190.

Advice context:

The All Wales Medicines Strategy Group (AWMSG) takes into account the National Institute for Health and Clinical Excellence (NICE) future work programme when considering whether a product will be appraised. To avoid duplication of effort, AWMSG would not normally consider undertaking an appraisal if NICE intend to publish final advice for the same product within twelve months of the projected Form B submission date. AWMSG advice is interim to that of NICE, should NICE subsequently publish guidance.

The above medicine cannot be endorsed for use within NHS Wales as an appraisal by NICE or AWMSG has not been undertaken. The medicine should NOT be prescribed routinely within NHS Wales for the indication stated above.

In the absence of guidance issued by NICE or AWMSG, clinicians should continue to exercise their clinical judgement when providing care for an individual patient. This should be in consultation with the patient and/or guardian or carer, based on the best available evidence.

This statement will be removed on receipt of a submission (i.e. the full submission [Forms A and B] or limited submission [Forms A and C]) or when final NICE guidance becomes available.